AG20159/AG/NIA NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2003	1
2004	2
2005	2
2006	2
2007	2
2008	1
2009	2
2010	1
2012	1
2013	1
2024	0

1

Amyloid-beta immunotherapy for Alzheimer's disease.

Fu HJ, Liu B, Frost JL, Lemere CA. Fu HJ, et al. CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017. CNS Neurol Disord Drug Targets. 2010. PMID: 20205640 Free PMC article. Review.

2

Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.

Lemere CA. Lemere CA. Prog Brain Res. 2009;175:83-93. doi: 10.1016/S0079-6123(09)17506-4. Prog Brain Res. 2009. PMID: 19660650 Free PMC article. Review.

3

Novel Abeta immunogens: is shorter better?

Lemere CA, Maier M, Peng Y, Jiang L, Seabrook TJ. Lemere CA, et al. Curr Alzheimer Res. 2007 Sep;4(4):427-36. doi: 10.2174/156720507781788800. Curr Alzheimer Res. 2007. PMID: 17908047 Review.

4

Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.

Maier M, Seabrook TJ, Lemere CA. Maier M, et al. Neurodegener Dis. 2005;2(5):267-72. doi: 10.1159/000090367. Neurodegener Dis. 2005. PMID: 16909008 Review.

5

Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice.

Seabrook TJ, Thomas K, Jiang L, Bloom J, Spooner E, Maier M, Bitan G, Lemere CA. Seabrook TJ, et al. Neurobiol Aging. 2007 Jun;28(6):813-23. doi: 10.1016/j.neurobiolaging.2006.04.007. Epub 2006 May 24. Neurobiol Aging. 2007. PMID: 16725229

6

Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia.

Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar GM, Costantino IM, Carroll MC, Mayadas TN, Lemere CA. Fu H, et al. Glia. 2012 May;60(6):993-1003. doi: 10.1002/glia.22331. Epub 2012 Mar 21. Glia. 2012. PMID: 22438044 Free PMC article.

7

Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice.

Seabrook TJ, Iglesias M, Bloom JK, Spooner ET, Lemere CA. Seabrook TJ, et al. Vaccine. 2004 Sep 28;22(29-30):4075-83. doi: 10.1016/j.vaccine.2004.03.061. Vaccine. 2004. PMID: 15364459

8

Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Maier M, et al. J Neurosci. 2008 Jun 18;28(25):6333-41. doi: 10.1523/JNEUROSCI.0829-08.2008. J Neurosci. 2008. PMID: 18562603 Free PMC article.

9

Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.

Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE. Lemere CA, et al. Neurobiol Dis. 2003 Oct;14(1):10-8. doi: 10.1016/s0969-9961(03)00044-5. Neurobiol Dis. 2003. PMID: 13678662

10

MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice.

Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA. Liu B, et al. J Neurosci. 2013 Apr 17;33(16):7027-37. doi: 10.1523/JNEUROSCI.5924-12.2013. J Neurosci. 2013. PMID: 23595760 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year